Last reviewed · How we verify
NaCl 3% HS
NaCl 3% HS is a Small molecule drug developed by Ahmed Mohamed ELbadawy. It is currently in Phase 1 development. Also known as: Hypertonic saline.
NaCl 3% HS is a small molecule intervention used in clinical trials to study various conditions, including Hidradenitis Suppurativa (HS), Transurethral Resection of Prostate Syndrome, Cystic Fibrosis, Viral Bronchiolitis, and Bronchiolitis. The exact mechanism of action of NaCl 3% HS is not specified in the provided information, but it is classified as a small molecule.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | NaCl 3% HS |
|---|---|
| Also known as | Hypertonic saline |
| Sponsor | Ahmed Mohamed ELbadawy |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Impact of Discontinuing Hypertonic Saline in People With CF on Highly Effective CFTR Modulators- A SIMPLIFY Sub-Study (NA)
- Edinburgh and Lothian Virus Intervention Study in Kids (NA)
- Clearing Lungs With ENaC Inhibition in Primary Ciliary Dyskinesia (PHASE2)
- Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS) (PHASE2)
- Prophylaxis Versus Treatment for TURP Syndrome. (NA)
- Preventive Inhalation of Hypertonic Saline in Infants With Cystic Fibrosis (PHASE2)
- Effect of Hypertonic Saline on Mucus Clearance in Children Ages 5-12 With Cystic Fibrosis (NA)
- A Study of Hypertonic Saline for Infants Hospitalized With Bronchiolitis (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NaCl 3% HS CI brief — competitive landscape report
- NaCl 3% HS updates RSS · CI watch RSS
- Ahmed Mohamed ELbadawy portfolio CI
Frequently asked questions about NaCl 3% HS
What is NaCl 3% HS?
Who makes NaCl 3% HS?
Is NaCl 3% HS also known as anything else?
What development phase is NaCl 3% HS in?
Related
- Manufacturer: Ahmed Mohamed ELbadawy — full pipeline
- Also known as: Hypertonic saline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing